{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T13:54:37Z","timestamp":1780322077128,"version":"3.54.1"},"reference-count":29,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,16]],"date-time":"2023-08-16T00:00:00Z","timestamp":1692144000000},"content-version":"vor","delay-in-days":592,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1007\/s13311-021-01165-9","type":"journal-article","created":{"date-parts":[[2021,12,2]],"date-time":"2021-12-02T19:03:36Z","timestamp":1638471816000},"page":"325-333","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"title":["Immunogenicity and safety of mRNA COVID-19 vaccines in people with multiple sclerosis treated with different disease-modifying therapies"],"prefix":"10.1016","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7639-5104","authenticated-orcid":false,"given":"Fioravante","family":"Capone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Lucchini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Ferraro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Assunta","family":"Bianco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariagrazia","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Cicia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Cortese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Cruciani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"De Arcangelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"De Giglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Motolese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biagio","family":"Sancetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimiliano","family":"Mirabella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Di Lazzaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1007\/s13311-021-01165-9_bib1","unstructured":"[https:\/\/covid19.who.int] accessed on 18 Aug\u00a02021."},{"key":"10.1007\/s13311-021-01165-9_bib2","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.ijbiomac.2020.06.213","article-title":"Designing a novel mRNA vaccine against SARS-CoV-2: an immunoinformatics approach","volume":"162","author":"Ahammad","year":"2020","journal-title":"Int J Biol Macromol"},{"key":"10.1007\/s13311-021-01165-9_bib3","doi-asserted-by":"crossref","unstructured":"Centonze D, Rocca MA, Gasperini C, Kappos L, Hartung HP, Magyari M, et al. Disease-modifying therapies and SARS-CoV-2 vaccination in multiple sclerosis: an expert consensus.\u00a0J Neurol\u00a02021;1\u20138. https:\/\/doi.org\/10.1007\/s00415-021-10545-2.","DOI":"10.1007\/s00415-021-10545-2"},{"key":"10.1007\/s13311-021-01165-9_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102788","article-title":"Willingness to obtain COVID-19 vaccination in adults with multiple sclerosis in the United States","volume":"49","author":"Ehde","year":"2021","journal-title":"Multiple sclerosis and related disorders"},{"key":"10.1007\/s13311-021-01165-9_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102880","article-title":"Willingness to be vaccinated against COVID-19:an exploratory online survey in a Portuguese cohort of multiple sclerosis patients","volume":"51","author":"Serrazina","year":"2021","journal-title":"Multiple sclerosis and related disorders"},{"key":"10.1007\/s13311-021-01165-9_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102439","article-title":"Effects of MS disease-modifying therapies on responses to vaccinations: a review","volume":"45","author":"Ciotti","year":"2020","journal-title":"Multiple sclerosis and related disorders"},{"key":"10.1007\/s13311-021-01165-9_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2021.577599","article-title":"Safety and efficacy of COVID-19 vaccines in multiple sclerosis patients","volume":"356","author":"Kelly","year":"2021","journal-title":"J Neuroimmunol"},{"key":"10.1007\/s13311-021-01165-9_bib8","doi-asserted-by":"crossref","unstructured":"Chilimuri S, Mantri N, Gongati S, Zahid M, Sun H. COVID-19 vaccine failure in a patient with multiple sclerosis on ocrelizumab. Vaccines. 2021;9(3). https:\/\/doi.org\/10.3390\/vaccines9030219.","DOI":"10.3390\/vaccines9030219"},{"issue":"6","key":"10.1007\/s13311-021-01165-9_bib9","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1177\/13524585211003476","article-title":"COVID-19 vaccination in patients with multiple sclerosis: what we have learnt by February 2021","volume":"27","author":"Achiron","year":"2021","journal-title":"Multiple sclerosis (Houndmills, Basingstoke, England)"},{"issue":"7839","key":"10.1007\/s13311-021-01165-9_bib10","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/s41586-020-2852-1","article-title":"SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies","volume":"588","author":"Barnes","year":"2020","journal-title":"Nature"},{"issue":"7","key":"10.1007\/s13311-021-01165-9_bib11","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","article-title":"Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection","volume":"27","author":"Khoury","year":"2021","journal-title":"Nat Med"},{"key":"10.1007\/s13311-021-01165-9_bib12","article-title":"Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies","volume":"14","author":"Achiron","year":"2021","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1007\/s13311-021-01165-9_bib13","doi-asserted-by":"crossref","unstructured":"Guerrieri S, Lazzarin S, Zanetta C, Nozzolillo A, Filippi M, Moiola L. Serological response to SARS-CoV-2 vaccination in multiple sclerosis patients treated with fingolimod or ocrelizumab: an initial real-life experience.\u00a0J Neurol.\u00a02021:1\u20135. https:\/\/doi.org\/10.1007\/s00415-021-10663-x.","DOI":"10.1007\/s00415-021-10663-x"},{"key":"10.1007\/s13311-021-01165-9_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.neurol.2021.05.001","article-title":"Impact of disease-modifying treatments on humoral response after COVID-19 vaccination: a mirror of the response after SARS-CoV-2 infection","author":"Bigaut","year":"2021","journal-title":"Revue neurologique"},{"key":"10.1007\/s13311-021-01165-9_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102983","article-title":"COVID-19 vaccines in multiple sclerosis treated with cladribine or ocrelizumab","volume":"52","author":"Buttari","year":"2021","journal-title":"Multiple sclerosis and related disorders"},{"key":"10.1007\/s13311-021-01165-9_bib16","doi-asserted-by":"crossref","unstructured":"Gallo A, Capuano R, Donnarumma G, Bisecco A, Grimaldi E, Conte M, et al. Preliminary evidence of blunted humoral response to SARS-CoV-2 mRNA vaccine in multiple sclerosis patients treated with ocrelizumab. Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. 2021;1\u20134. https:\/\/doi.org\/10.1007\/s10072-021-05397-7.","DOI":"10.1016\/j.jns.2021.117795"},{"issue":"2","key":"10.1007\/s13311-021-01165-9_bib17","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"The Lancet Neurology"},{"issue":"50","key":"10.1007\/s13311-021-01165-9_bib18","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.15585\/mmwr.mm6950e2","article-title":"The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine - United States, December 2020","volume":"69","author":"Oliver","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1007\/s13311-021-01165-9_bib19","doi-asserted-by":"crossref","DOI":"10.1111\/ene.15028","article-title":"Safety of the BNT162b2 COVID-19 vaccine in multiple sclerosis (MS): early experience from a tertiary MS center in Israel","author":"Lotan","year":"2021","journal-title":"Eur J Neurol"},{"key":"10.1007\/s13311-021-01165-9_bib20","doi-asserted-by":"crossref","DOI":"10.1177\/17562864211038111","article-title":"Humoral response to SARS-CoV-2 mRNA vaccine in patients with multiple sclerosis treated with natalizumab","volume":"14","author":"Capuano","year":"2021","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1007\/s13311-021-01165-9_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103150","article-title":"Humoral response to SARS-CoV-2 COVID-19 vaccines in patients with multiple sclerosis treated with immune reconstitution therapies","volume":"54","author":"Drulovic","year":"2021","journal-title":"Multiple sclerosis and related disorders"},{"issue":"14","key":"10.1007\/s13311-021-01165-9_bib22","doi-asserted-by":"crossref","first-page":"e1999","DOI":"10.1212\/WNL.0000000000010380","article-title":"Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: the VELOCE study","volume":"95","author":"Bar-Or","year":"2020","journal-title":"Neurology"},{"key":"10.1007\/s13311-021-01165-9_bib23","doi-asserted-by":"crossref","unstructured":"Sormani MP, Salvetti M, Labauge P, Schiavetti I, Zephir H, Carmisciano L, et al. DMTs and Covid-19 severity in MS: a pooled analysis from Italy and France. 2021;8(8):1738\u201344. https:\/\/doi.org\/10.1002\/acn3.51408.","DOI":"10.1002\/acn3.51408"},{"key":"10.1007\/s13311-021-01165-9_bib24","doi-asserted-by":"crossref","unstructured":"Sormani MP, De Rossi N, Schiavetti I, Carmisciano L, Cordioli C, Moiola L, et al. Disease-modifying therapies and coronavirus disease 2019 severity in multiple sclerosis. 2021;89(4):780\u20139. https:\/\/doi.org\/10.1002\/ana.26028.","DOI":"10.1002\/ana.26028"},{"key":"10.1007\/s13311-021-01165-9_bib25","doi-asserted-by":"crossref","unstructured":"Harritsh\u00f8j LH, Gybel-Brask M, Afzal S, Kamstrup PR, J\u00f8rgensen CS, Thomsen MK, et al. Comparison of 16 serological SARS-CoV-2 immunoassays in 16 clinical laboratories.\u00a0J Clin Microbiol.\u00a02021;59(5). https:\/\/doi.org\/10.1128\/jcm.02596-20.","DOI":"10.1128\/JCM.02596-20"},{"key":"10.1007\/s13311-021-01165-9_bib26","article-title":"Interferon-gamma release assay testing to assess COVID-19 vaccination response in a SARS-CoV-2 seronegative patient on rituximab: a case report","author":"Ferguson","year":"2021","journal-title":"International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases"},{"key":"10.1007\/s13311-021-01165-9_bib27","doi-asserted-by":"crossref","unstructured":"Rolfes L, Pawlitzki M, Pfeuffer S, Nelke C, Lux A, Pul R, et al. Ocrelizumab extended interval dosing in multiple sclerosis in times of COVID-19. Neurology(R) neuroimmunology & neuroinflammation. 2021;8(5). https:\/\/doi.org\/10.1212\/nxi.0000000000001035.","DOI":"10.1212\/NXI.0000000000001035"},{"issue":"7","key":"10.1007\/s13311-021-01165-9_bib28","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1056\/NEJMc2108861","article-title":"Three doses of an mRNA Covid-19 vaccine in solid-organ transplant recipients","volume":"385","author":"Kamar","year":"2021","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1007\/s13311-021-01165-9_bib29","doi-asserted-by":"crossref","DOI":"10.1002\/jcla.23921","article-title":"Performance evaluation of three automated quantitative immunoassays and their correlation with a surrogate virus neutralization test in coronavirus disease 19 patients and pre-pandemic controls","volume":"35","author":"Jung","year":"2021","journal-title":"J Clin Lab Anal"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-021-01165-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13311-021-01165-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923001708?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923001708?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-021-01165-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T06:40:35Z","timestamp":1761806435000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923001708"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S1878747923001708"],"URL":"https:\/\/doi.org\/10.1007\/s13311-021-01165-9","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunogenicity and safety of mRNA COVID-19 vaccines in people with multiple sclerosis treated with different disease-modifying therapies","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-021-01165-9","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2022 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}